StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Friday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Trading Up 3.2 %

OpGen stock opened at $1.96 on Friday. The company has a 50 day moving average of $2.49 and a 200-day moving average of $3.87. OpGen has a twelve month low of $1.75 and a twelve month high of $38.40.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Monday, July 8th. The medical research company reported $0.21 earnings per share (EPS) for the quarter. OpGen had a negative net margin of 1,140.36% and a negative return on equity of 1,827.76%. The company had revenue of $0.17 million for the quarter.

Hedge Funds Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp bought a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent quarter. Institutional investors own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.